WO2013168024A1 - Prodrugs of anti-platelet agents - Google Patents

Prodrugs of anti-platelet agents Download PDF

Info

Publication number
WO2013168024A1
WO2013168024A1 PCT/IB2013/052328 IB2013052328W WO2013168024A1 WO 2013168024 A1 WO2013168024 A1 WO 2013168024A1 IB 2013052328 W IB2013052328 W IB 2013052328W WO 2013168024 A1 WO2013168024 A1 WO 2013168024A1
Authority
WO
WIPO (PCT)
Prior art keywords
independently
administration
formula
compound
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2013/052328
Other languages
English (en)
French (fr)
Inventor
Mahesh Kandula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2012/053673 external-priority patent/WO2013024376A1/en
Priority to SG11201407307YA priority Critical patent/SG11201407307YA/en
Priority to CA2873094A priority patent/CA2873094A1/en
Priority to AU2013257745A priority patent/AU2013257745A1/en
Priority to CN201380030644.9A priority patent/CN104379589A/zh
Priority to EP13787471.5A priority patent/EP2847197A4/en
Application filed by Individual filed Critical Individual
Priority to JP2015510901A priority patent/JP2015519334A/ja
Publication of WO2013168024A1 publication Critical patent/WO2013168024A1/en
Priority to PCT/IB2014/058090 priority patent/WO2014118649A2/en
Priority to ZA2014/08064A priority patent/ZA201408064B/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Definitions

  • a is independently 2,3 or 7;
  • each b is i ndependently 3, 5 or 6;
  • polymorph as used herein is art-recognized and refers to one crystal structure of a. given compound.
  • the compounds of Formulas i may be administered at a dose of, for example, less than 0.2 mg kg day, 0.5 mg/kg/day, 1.0 mg/kg day, 5 mg/kg/day, 10 mg/kg/day, 20 mg/kg/day, 30 mg kg day, or 40 mg/kg/day.
  • Compounds of Formula I, formula 11, formula la or formula Il may also be administered to a human patient at a dose of, for example, between 0. 1 mg and 1000 mg, between 5 nig and 80 mg, or less than 1.0. 9.0, 12.0, 20.0, 50.0, 75.0, 100, 300, 400, 500, 800, 1000, 2000, 5000 mg per day.
  • a method for the manufacture of the above-mentioned substrate sheet comprises preparing the above resin composition molding the resin composition into a composite film by a calendar process, and then adhering a polyaikyiene terephthaiate film on. one side of the composite film by means of an adhesive layer thereby forming the substrate sheet, and forming a primer layer comprising a saturated polyester resin on the outer surface of the polyaikyiene terephthaiate film.
  • c and d are each independently H, D, -OH, -OD, C Qralkyi, - H? or -COC3 ⁇ 4.
  • M ihi is for using compounds of formula I:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
PCT/IB2013/052328 2012-05-07 2013-03-24 Prodrugs of anti-platelet agents Ceased WO2013168024A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2015510901A JP2015519334A (ja) 2012-05-07 2013-03-24 抗血小板薬のプロドラッグ
CA2873094A CA2873094A1 (en) 2012-05-07 2013-03-24 Prodrugs of anti-platelet agents
AU2013257745A AU2013257745A1 (en) 2012-05-07 2013-03-24 Prodrugs of anti-platelet agents
CN201380030644.9A CN104379589A (zh) 2012-05-07 2013-03-24 抗血小板药剂的前药
EP13787471.5A EP2847197A4 (en) 2012-05-07 2013-03-24 PRODRUGS OF ANTIBODY AGENTS
SG11201407307YA SG11201407307YA (en) 2012-05-07 2013-03-24 Prodrugs of anti-platelet agents
PCT/IB2014/058090 WO2014118649A2 (en) 2013-01-19 2014-01-07 Compositions and methods for the treatment of cardiovascular diseases
ZA2014/08064A ZA201408064B (en) 2012-05-07 2014-11-04 Prodrugs of anti-platelet agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1781CH2012 2012-05-07
IN1781/CHE/2012 2012-05-07
IBPCT/IB2012/053673 2012-07-19
PCT/IB2012/053673 WO2013024376A1 (en) 2011-08-16 2012-07-19 Compositions and methods for the treatment of atherothrombosis

Publications (1)

Publication Number Publication Date
WO2013168024A1 true WO2013168024A1 (en) 2013-11-14

Family

ID=54193687

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/052328 Ceased WO2013168024A1 (en) 2012-05-07 2013-03-24 Prodrugs of anti-platelet agents

Country Status (8)

Country Link
EP (1) EP2847197A4 (https=)
JP (1) JP2015519334A (https=)
CN (1) CN104379589A (https=)
AU (1) AU2013257745A1 (https=)
CA (1) CA2873094A1 (https=)
SG (1) SG11201407307YA (https=)
WO (1) WO2013168024A1 (https=)
ZA (1) ZA201408064B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117343000A (zh) * 2020-07-29 2024-01-05 上海柯君医药科技有限公司 抗血小板药物和其用途
CN119019320A (zh) * 2024-10-29 2024-11-26 上海柯君医药科技有限公司 一种具有抗血小板活性的哌啶类化合物的制备方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201407328TA (en) * 2012-07-03 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of moderate to severe pain
CN114507157B (zh) * 2020-11-17 2023-03-24 沧州维智达美制药有限公司 一种利用氯乙腈制备溴乙腈的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005046575A2 (en) * 2003-07-29 2005-05-26 Signature R & D Holdings, Lcc Amino acid prodrugs
EP2298777A2 (en) * 2008-06-09 2011-03-23 Enzytech, Ltd. Method for preparing clopidogrel and its derivatives
CN102002053A (zh) * 2009-09-02 2011-04-06 陕西合成药业有限公司 用于治疗的四氢噻吩并吡啶衍生物
CN102336767A (zh) * 2011-07-11 2012-02-01 华东理工大学 制备高纯度手性α-取代-6,7-二氢噻吩并[3,2-c]吡啶衍生物的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858734B2 (en) * 2003-04-23 2005-02-22 Rhodia Pharma Solutions Inc. Preparation of (S)-Clopidogrel and related compounds
EP1889835A4 (en) * 2005-05-27 2010-04-28 Daiichi Sankyo Co Ltd CYCLIC AMINE DERIVATIVE WITH SUBSTITUTED ALKYL GROUP
WO2013024376A1 (en) * 2011-08-16 2013-02-21 Mahesh Kandula Compositions and methods for the treatment of atherothrombosis
US9525998B2 (en) * 2012-01-06 2016-12-20 Qualcomm Incorporated Wireless display with multiscreen service
JP6097766B2 (ja) * 2012-01-27 2017-03-15 インターデイジタル パテント ホールディングス インコーポレイテッド マルチキャリアベースおよび／または疑似照合ネットワークにおいてｅｐｄｃｃｈを提供するためのシステムおよび／または方法
WO2013167985A1 (en) * 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological disorders
SG11201407317SA (en) * 2012-05-08 2014-12-30 Cellix Bio Private Ltd Compositions and methods for suppression of carbonic anhydrase activity
WO2013167987A1 (en) * 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of diabetes
JP2015526385A (ja) * 2012-05-08 2015-09-10 セリックスビオ プライヴェート リミテッド てんかんの治療のための組成物及び方法
CA2872976A1 (en) * 2012-05-08 2013-11-14 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
SG11201407328TA (en) * 2012-07-03 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of moderate to severe pain

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005046575A2 (en) * 2003-07-29 2005-05-26 Signature R & D Holdings, Lcc Amino acid prodrugs
EP2298777A2 (en) * 2008-06-09 2011-03-23 Enzytech, Ltd. Method for preparing clopidogrel and its derivatives
CN102002053A (zh) * 2009-09-02 2011-04-06 陕西合成药业有限公司 用于治疗的四氢噻吩并吡啶衍生物
CN102336767A (zh) * 2011-07-11 2012-02-01 华东理工大学 制备高纯度手性α-取代-6,7-二氢噻吩并[3,2-c]吡啶衍生物的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2847197A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117343000A (zh) * 2020-07-29 2024-01-05 上海柯君医药科技有限公司 抗血小板药物和其用途
CN119019320A (zh) * 2024-10-29 2024-11-26 上海柯君医药科技有限公司 一种具有抗血小板活性的哌啶类化合物的制备方法

Also Published As

Publication number Publication date
SG11201407307YA (en) 2014-12-30
AU2013257745A1 (en) 2014-11-27
JP2015519334A (ja) 2015-07-09
EP2847197A1 (en) 2015-03-18
ZA201408064B (en) 2016-04-28
CA2873094A1 (en) 2013-11-14
CN104379589A (zh) 2015-02-25
EP2847197A4 (en) 2015-11-04

Similar Documents

Publication Publication Date Title
WO2013168022A1 (en) Compositions and methods for treating atherothrombosis
EP2847152A1 (en) Compositions and methods for the treatment of metabolic syndrome
US9492409B2 (en) Compositions and methods for the treatment of local pain
WO2013168024A1 (en) Prodrugs of anti-platelet agents
US9403826B2 (en) Compositions and methods for the treatment of inflammatory disorders
WO2013168008A1 (en) Compositions and methods for the treatment of neurological diseases
WO2013167986A2 (en) Compositions and methods for the treatment of epilepsy
WO2014195850A2 (en) Compositions and methods for the treatment of neurologic diseases and neurological disorders
WO2014068506A2 (en) Compositions and methods for the treatment of autoimmune diseases
WO2013175344A2 (en) Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9242939B2 (en) Compositions and methods for the treatment of respiratory disorders
US9346742B2 (en) Compositions and methods for the treatment of fibromyalgia pain
US9403857B2 (en) Compositions and methods for the treatment of metabolic syndrome
WO2014118649A2 (en) Compositions and methods for the treatment of cardiovascular diseases
WO2015028976A2 (en) Compounds and methods for the treatment of inflammatory diseases
US20150087697A1 (en) Compositions and methods for the treatment of muscle pain
WO2014057439A2 (en) Compositions and methods for the treatment of neurological diseases and its associated complications
US9309233B2 (en) Compositions and methods for the treatment of blood clotting disorders
US9175008B1 (en) Prodrugs of anti-platelet agents
US9227974B2 (en) Compositions and methods for the treatment of respiratory disorders
WO2014147541A2 (en) Compositions and methods for the treatment of peptic ulcers and gastrointestinal diseases
WO2015022613A1 (en) Compositions and methods for the treatment of diabetes and pre-diabetes
WO2015028956A1 (en) Compositions and methods for the treatment of fatty acid oxidation disorders
WO2013167995A2 (en) Compositions and methods for the treatment of hyperglycemia
WO2014049471A1 (en) Compositions and methods for the treatment of ventricular arrhythmias and cardiovascular diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13787471

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2015510901

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2873094

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2013787471

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013257745

Country of ref document: AU

Date of ref document: 20130324

Kind code of ref document: A